Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions
April 22, 2016
This low rate of target lesion revascularization translated into meaningful clinical improvement for the majority of patients, with both the average walking distance and average walking speed more than doubling following Zilver PTX stent implantation, and being sustained to two years. In addition there was a very good safety profile, and a very low rate of stent fractures."These interim data suggest this device is safe and efficacious for the treatment of SFA lesions," said William A. ...
Peptides: A new clue on the origins of life
April 21, 2016
Working with Anil Mehta, a chemistry post-doctoral fellow, Childers tagged one end of peptide chains with an NMR label, and then allowed them to assemble to see if the ends would interact. The result was a bi-layer membrane with inner and outer faces and an additional, buried layer that localized functionality within the interior. "The peptide membranes combine the long-range structure of cell membranes with the local order of enzymes," Childers said. "Now that we understand that ...
Annual heart disease and stroke rates in China to rise up to 73% by 2030: Research
April 20, 2016
Reducing smoking to 20 percent of the male population by 2020 and 10 percent by 2030, or lowering average systolic blood pressure by four points in men and women, would significantly counteract adverse trends in other risk factors and prevent between 2.9 and 5.7 million deaths by 2030, according to the study. Aggressive anti-tobacco policies and preventive efforts aimed at controlling elevated blood pressure are two promising areas that need to be studied in more detail, Dr. Moran said."Chi...
Older men who receive pneumococcal vaccine not less likely to have heart attack, stroke: JAMA
April 19, 2016
Business Execution Highlights Completed Key Technology Transfer Objectives with Takeda Alliance and Earned $20 Million Payment. Alnylam earned a $20 million technology transfer payment from Takeda as part of the strategic alliance the companies formed in May 2008. This payment is related to the achievement of certain pre-defined objectives in the transfer of Alnylam's platform technology, including documents, materials, and know-how, to Takeda for the development of RNAi therapeutics. Alnylam ha...
Australian researchers show positive effect of growth hormone on athletic performance
April 18, 2016
"Those athletes given growth hormone improved their sprint capacity by 4-5%," said Professor Ho."Growth hormone recipients did not increase their muscle mass. They did, however, retain body fluid and experienced swelling and joint pain, unlike those who received salt water injections." "We used lower doses of growth hormone than athletes are reported to use, and for a shorter time. We can speculate, therefore, that the drug's effects on performance might be greater than ...